In this study, we evaluated the performance of a new blood‐based early CRC screening assay, ColoDefense test, which combined the detection of SEPT9 and SDC2 methylation in a single qPCR reaction to improve the detection rate for early stage CRC and AA. Here, SDC2 is linked to colorectal carcinoma.